"The CDC and the New Jersey Department of Health have confirmed a death from Lassa fever which was diagnosed earlier today in a person returning to the United States from Liberia. The patient traveled from Liberia to Morocco to JFK International A"...
The use of Trecator (ethionamide tablets) alone in the treatment of tuberculosis results in rapid development of resistance. It is essential, therefore, to give a suitable companion drug or drugs, the choice being based on the results of susceptibility testing. However, therapy may be initiated prior to receiving the results of susceptibility tests as deemed appropriate by the physician. Ethionamide should be administered with at least one, sometimes two, other drugs to which the organism is known to be susceptible (see INDICATIONS AND USAGE). Drugs which have been used as companion agents are rifampin, ethambutol, pyrazinamide, cycloserine, kanamycin, streptomycin, and isoniazid. The usual warnings, precautions, and dosage regimens for these companion drugs should be observed.
Patient compliance is essential to the success of the antituberculosis therapy and to prevent the emergence of drug-resistant organisms. Therefore, patients should adhere to the drug regimen for the full duration of treatment. It is recommended that directly observed therapy be practiced when patients are receiving antituberculous medication. Additional consultation from experts in the treatment of drug-resistant tuberculosis is recommended when patients develop drug-resistant organisms.
Ethionamide may potentiate the adverse effects of the other antituberculous drugs administered concomitantly (see DRUG INTERACTIONS). Ophthalmologic examinations (including ophthalmoscopy) should be performed before and periodically during therapy with Trecator (ethionamide tablets) .
Determination of serum transaminases (SGOT, SGPT) should be made prior to initiation of therapy and should be monitored monthly. If serum transaminases become elevated during therapy, ethionamide and the companion antituberculosis drug or drugs may be discontinued temporarily until the laboratory abnormalities have resolved. Ethionamide and the companion antituberculosis medication(s) then should be reintroduced sequentially to determine which drug (or drugs) is (are) responsible for the hepatotoxicity.
Blood glucose determinations should be made prior to and periodically throughout therapy with Trecator (ethionamide tablets) . Diabetic patients should be particularly alert for episodes of hypoglycemia.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Teratogenic Effects: Pregnancy Category C
Animal studies conducted with Trecator (ethionamide tablets) indicate that the drug has teratogenic potential in rabbits and rats. The doses used in these studies on a mg/kg basis were considerably in excess of those recommended in humans. There are no adequate and well-controlled studies in pregnant women. Because of these animal studies, however, it must be recommended that Trecator (ethionamide tablets) be withheld from women who are pregnant, or who are likely to become pregnant while under therapy, unless the prescribing physician considers it to be an essential part of the treatment.
Labor and Delivery
The effect of Trecator (ethionamide tablets) on labor and delivery in pregnant women is unknown.
Because no information is available on the excretion of ethionamide in human milk, Trecator (ethionamide tablets) should be administered to nursing mothers only if the benefits outweigh the risks. Newborns who are breast-fed by mothers who are taking Trecator (ethionamide tablets) should be monitored for adverse effects.
Due to the fact that pulmonary tuberculosis resistant to primary therapy is rarely found in neonates, infants, and children, investigations have been limited in these age groups. At present, the drug should not be used in pediatric patients under 12 years of age except when the organisms are definitely resistant to primary therapy and systemic dissemination of the disease, or other life-threatening complications of tuberculosis, is judged to be imminent.
Last reviewed on RxList: 6/15/2007
This monograph has been modified to include the generic and brand name in many instances.
Additional Trecator Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.